Dr J_Rg Denzler

Dr. Jörg Denzler is a Swiss company director whose clearest public operating role is as a member of the Board of Directors of Neoperl Group AG. Neoperl describes itself as a German-Swiss, family-owned technology company based in Reinach-Basel that develops products for drinking-water applications, including faucet aerators, flow regulators, check valves, and hoses.

Swiss registry aggregators list Dr. Jörg Denzler, of Zurich and resident in Zollikon, as active in several Swiss entities, including Neoperl AG, Neoperl Group AG, Diaqua AG, Balanx AG, Superhuman GmbH, and Stiftung BEST Art Collection Luzern. These records point to a profile centered on private-company governance and entrepreneurial holdings rather than a public venture-capital fund role.

In Superhuman GmbH, a Zurich company formed in 2020 to organize and run cultural events, Moneyhouse lists Dr. Jörg Denzler as a manager/signatory. A May 30, 2025 Swiss commercial-register notice reported that he became shareholder and chair of management with 13 of the company’s 20 CHF 1,000 quota shares, increased from 7 shares.

I found no public source verifying the stub’s claim that he is affiliated with Spectrum Value Management Ltd. or that `[hidden]` is his personal email. That address is publicly listed for Spectrum Value Management Ltd., a separate Swiss family office associated with the Thomas Schmidheiny family.

• No public investment thesis, check size, or founder-facing investment criteria were found for Dr. Jörg Denzler.
• Public records support a focus on Swiss private-company governance and operating involvement rather than a conventional angel-investor profile.
• His verifiable activity includes industrial technology via Neoperl, communications consulting via Balanx AG, and cultural-event activity via Superhuman GmbH.
• For founders, the most defensible relevance is likely around Swiss industrial, family-business, water-technology, communications, or culture-related opportunities rather than broad software or venture-scale seed investing.